ERBB2 and breast carcinoma: It was available for use in the UK from September 2017 on the patient access scheme and approved by the National Institute for Health and Care Excellence (NICE) in December 2017 for use in combination with an AI for the treatment of ER+/HER2-advanced breast cancer in the first-line setting [5].